Libtayo’s CSCC Label Expansion Broadens Practitioner Base

 
• By Alaric DeArment
  
Regeneron won FDA approval for Libtayo in adjuvant treatment of CSCC. (Alaric DeArment)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer